Shaanxi Xiyue Pharmaceutical Co Ltd.

Primary objective: To use the vonoprazan fumarate tablets developed by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test preparation and the vonoprazan fumarate tablets (trade name: Walker®) certified by Takeda Pharmaceutical Company Limited as the reference preparation, to investigate the pharmacokinetic parameters and relative bioavailability of the two preparations in the fasting and postprandial state after a single administration, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To evaluate the safety of the test and reference preparations of vonoprazan fumarate tablets after a single oral administration on an empty stomach/postprandial basis in healthy Chinese subjects.

Primary objective: Using febuxostat tablets (trade name: Feburic, specification: 40 mg) from Teijin Pharma Limited as the reference preparation and febuxostat tablets (40 mg) developed by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test preparation, a single-center, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, crossover clinical trial was conducted to evaluate the bioequivalence of the two preparations in fasting and fed states in healthy Chinese subjects. Secondary objective: To observe the safety of the test preparation and reference preparation in healthy Chinese subjects.